Drug pricing has taken center stage in U.S. politics, and it’s high time that it should. The soaring prices for drugs like Sovaldi ($1,000 a pill) and the recent hike of Deraprim from $13.50 to $750 a pill after the supplier was bought by a shady hedge-fund manager, have caused white-hot fury in the public. Corporate lobbyists and their friends in the media spout free-market platitudes about why the sky-high prices are necessary to promote innovation. It’s time for a serious understanding of the policy issues.
- Earth 2.0: Is Income Inequality Inevitable?
- Will Economic Illiteracy Trigger a Trade War?
- How Trump could make US a climate pariah over Paris pact
- Earth 2.0: What Would Our Economy Look Like?
- Our misguided ‘wars of choice’